An international clinical trial involving 11 countries reports strong tumour responses from a new “triple-action” cancer injection in people whose cancer has spread or returned and who no longer respond to standard treatments. According to reports from multiple outlets, the therapy is tested in patients with cancers that have become resistant to chemotherapy and immunotherapy, and clinicians describe the results as unusually strong. In several cases cited by the media coverage, the injection eradicates entire tumours in treatment-resistant patients, producing what researchers and specialists call “unprecedented” or “striking” outcomes. The trial findings are presented as early evidence of effectiveness in a group with limited remaining treatment options, and the coverage frames the results as promising rather than definitive. The sources do not describe all study details, such as cancer types involved, dosing, trial size, or long-term outcomes, but they broadly agree that the jab produces major tumour reductions—including complete responses—in participants who have exhausted other therapies.